Quick Answer
Imunon, Inc. reported Cash and Equivalents of $8.78 million for fiscal year 2025.
Imunon, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $8.78M | +49.5% |
| 2024 | $5.87M | +0.6% |
| 2023 | $5.84M | -49.2% |
| 2022 | $11.49M | -41.3% |
| 2021 | $19.59M | +14.1% |
| 2020 | $17.16M | +149.7% |
| 2019 | $6.88M | -48.5% |
| 2018 | $13.35M | +16.7% |
| 2017 | $11.44M | +336.1% |
| 2016 | $2.62M | -71.7% |
| 2015 | $9.27M | -27.0% |
| 2014 | $12.69M | +121.9% |
| 2013 | $5.72M | -61.9% |
| 2012 | $14.99M | -25.6% |
| 2011 | $20.15M | +1668.9% |
| 2010 | $1.14M | -83.5% |
| 2009 | $6.92M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $5.25M | -49.1% | +11.0% |
| June 30, 2025 | $4.73M | -10.9% | +64.7% |
| March 31, 2025 | $2.87M | +22.4% | -51.1% |
| December 31, 2024 | $5.87M | +0.6% | -43.0% |
| September 30, 2024 | $10.31M | -20.0% | +94.3% |
| June 30, 2024 | $5.31M | -19.7% | +126.1% |
| March 31, 2024 | $2.35M | -77.4% | -59.8% |
| December 31, 2023 | $5.84M | -49.2% | -54.7% |
- Imunon, Inc. showed an increase of +49.5% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2009–2025 period, Imunon, Inc.’s cash and equivalents has grown by 26.8% (from $6.92 million to $8.78 million).
- The most recent figure is from Imunon, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 31, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: